Please use this identifier to cite or link to this item:
https://dora.health.qld.gov.au/qldresearchjspui/handle/1/3912
Full metadata record
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Revesz, T. | en |
dc.contributor.author | Law, T. | en |
dc.contributor.author | Ong, E. | en |
dc.contributor.author | Heatley, S. L. | en |
dc.contributor.author | McClure, B. J. | en |
dc.contributor.author | Meyer, C. | en |
dc.contributor.author | Marschalek, R. | en |
dc.contributor.author | Henderson, M. J. | en |
dc.contributor.author | Cross, S. | en |
dc.contributor.author | White, D. L. | en |
dc.contributor.author | Kotecha, R. S. | en |
dc.contributor.author | Khaw, S. L. | en |
dc.contributor.author | Fraser, C. | en |
dc.contributor.author | Bateman, C. M. | en |
dc.contributor.author | Trahair, T. N. | en |
dc.contributor.author | Mitchell, R. | en |
dc.contributor.author | Venn, N. C. | en |
dc.contributor.author | Chamberlain, J. | en |
dc.contributor.author | Sutton, R. | en |
dc.contributor.author | Pozza, L. D. | en |
dc.date.accessioned | 2022-11-07T23:47:24Z | - |
dc.date.available | 2022-11-07T23:47:24Z | - |
dc.date.issued | 2021 | en |
dc.identifier.citation | 68, (5), 2021 | en |
dc.identifier.other | RIS | en |
dc.identifier.uri | http://dora.health.qld.gov.au/qldresearchjspui/handle/1/3912 | - |
dc.description.abstract | We report on the Australian experience of blinatumomab for treatment of 24 children with relapsed/refractory precursor B-cell acute lymphoblastic leukaemia (B-ALL) and high-risk genetics, resulting in a minimal residual disease (MRD) response rate of 58%, 2-year progression-free survival (PFS) of 39% and 2-year overall survival of 63%. In total, 83% (n = 20/24) proceeded to haematopoietic stem cell transplant, directly after blinatumomab (n = 12) or following additional salvage therapy (n = 8). Four patients successfully received CD19-directed chimeric antigen receptor T-cell therapy despite prior blinatumomab exposure. Inferior 2-year PFS was associated with MRD positivity (20%, n = 15) and in KMT2A-rearranged infants (15%, n = 9). Our findings highlight that not all children with relapsed/refractory B-ALL respond to blinatumomab and factors such as blast genotype may affect prognosis.L20106060732021-03-08 <br /> | en |
dc.language.iso | en | en |
dc.relation.ispartof | Pediatric Blood and Cancer | en |
dc.title | Outcomes for Australian children with relapsed/refractory acute lymphoblastic leukaemia treated with blinatumomab | en |
dc.type | Article | en |
dc.identifier.doi | 10.1002/pbc.28922 | en |
dc.subject.keywords | leukemia remission | en |
dc.subject.keywords | male | en |
dc.subject.keywords | minimal residual disease | en |
dc.subject.keywords | multiple cycle treatment | en |
dc.subject.keywords | overall survival | en |
dc.subject.keywords | pre B lymphocyte | en |
dc.subject.keywords | priority journal | en |
dc.subject.keywords | progression free survival | en |
dc.subject.keywords | relapsed refractory acute lymphoblastic leukemia | en |
dc.subject.keywords | treatment response | en |
dc.subject.keywords | tumor gene | en |
dc.subject.keywords | salvage therapy | en |
dc.subject.keywords | 2016-004674-17NCT02393859 | en |
dc.subject.keywords | blinatumomab | en |
dc.subject.keywords | CD19 antigen | en |
dc.subject.keywords | dasatinib | en |
dc.subject.keywords | inotuzumab ozogamicin | en |
dc.subject.keywords | mixed lineage leukemia protein | en |
dc.subject.keywords | nilotinib | en |
dc.subject.keywords | venetoclax | en |
dc.subject.keywords | acute lymphoblastic leukemia | en |
dc.subject.keywords | article | en |
dc.subject.keywords | Australia | en |
dc.subject.keywords | cancer prognosis | en |
dc.subject.keywords | cancer recurrence | en |
dc.subject.keywords | cancer survival | en |
dc.subject.keywords | CD3+ T lymphocyte | en |
dc.subject.keywords | child | en |
dc.subject.keywords | childhood leukemia | en |
dc.subject.keywords | chimeric antigen receptor T-cell immunotherapy | en |
dc.subject.keywords | clinical article | en |
dc.subject.keywords | clinical outcome | en |
dc.subject.keywords | clinical trial | en |
dc.subject.keywords | disease burden | en |
dc.subject.keywords | drug exposure | en |
dc.subject.keywords | event free survival | en |
dc.subject.keywords | female | en |
dc.subject.keywords | follow up | en |
dc.subject.keywords | gene rearrangement | en |
dc.subject.keywords | genetic risk | en |
dc.subject.keywords | hematopoietic stem cell transplantation | en |
dc.subject.keywords | human | en |
dc.subject.keywords | kmt2a gene | en |
dc.subject.keywords | leukemia relapse | en |
dc.relation.url | https://www.embase.com/search/results?subaction=viewrecord&id=L2010606073&from=exporthttp://dx.doi.org/10.1002/pbc.28922 | | en |
dc.identifier.risid | 2801 | en |
item.cerifentitytype | Publications | - |
item.openairecristype | http://purl.org/coar/resource_type/c_18cf | - |
item.languageiso639-1 | en | - |
item.openairetype | Article | - |
item.grantfulltext | none | - |
item.fulltext | No Fulltext | - |
Appears in Sites: | Children's Health Queensland Publications |
Items in DORA are protected by copyright, with all rights reserved, unless otherwise indicated.